Company Filing History:
Years Active: 2014
Title: Katherine McJunkin: Innovator in Cancer Research
Introduction
Katherine McJunkin is a prominent inventor based in Cold Spring Harbor, NY (US). She has made significant contributions to the field of cancer research, particularly in the development of innovative therapies for chemotherapy-resistant leukemia and other cancers. Her work is characterized by a commitment to advancing medical science and improving patient outcomes.
Latest Patents
Katherine McJunkin holds a patent for the "Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers." This patent describes a mosaic mouse model designed to evaluate the effectiveness of short hairpin RNA (shRNA) in vivo for reducing the survival of cancer cells associated with chemotherapy-resistant leukemia. The model involves transplanting a syngeneic mouse recipient with tet-on competent leukemia cells that carry a bicistronic nucleic acid construct. This construct includes a promoter linked to a fusion gene related to chemotherapy-resistant leukemia and a sequence encoding a reverse tet-transactivator protein, allowing for co-expression of both coding sequences from the promoter. Additionally, the patent outlines methods for treating soft tissue cancers.
Career Highlights
Katherine McJunkin is affiliated with Cold Spring Harbor Laboratory, where she conducts her research. Her work has garnered attention for its innovative approach to tackling complex cancer challenges. With a focus on RNA interference (RNAi) technology, she has positioned herself as a key figure in the ongoing fight against cancer.
Collaborations
Katherine has collaborated with notable scientists in her field, including Bruce W. Stillman and Scott William Lowe. These partnerships have further enhanced her research and contributed to the advancement of cancer therapies.
Conclusion
Katherine McJunkin's contributions to cancer research through her innovative patent and collaborative efforts highlight her dedication to improving treatment options for patients facing chemotherapy-resistant leukemia and other cancers. Her work continues to inspire advancements in medical science.